The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.
President Joe Biden's signature Inflation Reduction Act , signed into law last year, allows the Medicare health program for Americans aged 65 and over to negotiate prices for some of its most costly drugs.
Our Standards:Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Biden administration to target drugs for price negotiations to lower Medicare costsPresident Joe Biden’s administration is set to announce the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower Medicare costs.
Consulte Mais informação »
Biden administration to target drugs for price negotiations to lower Medicare costsPresident Joe Biden’s administration is set to announce the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower Medicare costs
Consulte Mais informação »
Biden administration to target drugs for price negotiations to lower Medicare costsPresident Joe Biden’s administration is set to announce the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower Medicare costs.
Consulte Mais informação »
Biden administration to target drugs for price negotiations to lower Medicare costsPresident Joe Biden’s administration is set to announce the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower Medicare costs.
Consulte Mais informação »
Biden administration to target drugs for price negotiations to lower Medicare costsPresident Joe Biden’s administration is set to announce the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower Medicare costs.
Consulte Mais informação »